BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 12671884)

  • 1. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
    Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
    Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
    Wolf JM; Rybicki LA; Lashner BA
    Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Tung BY; Emond MJ; Haggitt RC; Bronner MP; Kimmey MB; Kowdley KV; Brentnall TA
    Ann Intern Med; 2001 Jan; 134(2):89-95. PubMed ID: 11177311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
    Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
    Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
    Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodiol for all?
    Lee SD; Surawicz CM
    Am J Gastroenterol; 2001 Dec; 96(12):3437-8. PubMed ID: 11774966
    [No Abstract]   [Full Text] [Related]  

  • 8. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.
    Ashraf I; Choudhary A; Arif M; Matteson ML; Hammad HT; Puli SR; Bechtold ML
    Indian J Gastroenterol; 2012 Apr; 31(2):69-74. PubMed ID: 22528343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ulcerative colitis. Cancer prevention].
    Schmiegel W; Pox C; Kroesen A
    Z Gastroenterol; 2004 Sep; 42(9):1014-8. PubMed ID: 15455276
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.
    Moayyeri A; Daryani NE; Bahrami H; Haghpanah B; Nayyer-Habibi A; Sadatsafavi M
    J Gastroenterol Hepatol; 2005 Mar; 20(3):366-70. PubMed ID: 15740478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk].
    MMW Fortschr Med; 2006 Jun; 148(24):42-3. PubMed ID: 16850808
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of colon cancer with ursodiol in ulcerative colitis.
    Kim HS
    Inflamm Bowel Dis; 2001 Aug; 7(3):279-80. PubMed ID: 11515858
    [No Abstract]   [Full Text] [Related]  

  • 13. Ulcerative colitis and an abnormal cholangiogram.
    Nguyen DL; Lazaridis KN
    Cleve Clin J Med; 2011 May; 78(5):306-11. PubMed ID: 21536825
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colorectal cancer in ulcerative colitis.
    Croog VJ; Ullman TA; Itzkowitz SH
    Int J Colorectal Dis; 2003 Sep; 18(5):392-400. PubMed ID: 12904996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research.
    Hawk ET; Viner JL
    Ann Intern Med; 2001 Jan; 134(2):158-60. PubMed ID: 11177320
    [No Abstract]   [Full Text] [Related]  

  • 18. Mucin-producing carcinoma of the gallbladder associated with primary sclerosing cholangitis and ulcerative colitis.
    Noda H; Chiba F; Toyama N; Konishi F
    J Hepatobiliary Pancreat Surg; 2009; 16(1):83-5. PubMed ID: 19096754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.
    D'Haens GR; Lashner BA; Hanauer SB
    Am J Gastroenterol; 1993 Aug; 88(8):1174-8. PubMed ID: 8338083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.